415912-62-8

Basic information

• Product Name: Methyl 2-(2-Methyl-4-nitrophenyl)acetate
• Synonyms: Methyl 2-(2-Methyl-4-nitrophenyl)acetate
• CAS NO: 415912-62-8
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 209.19864
• Mol File: 415912-62-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(2-Methyl-4-nitrophenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(2-Methyl-4-nitrophenyl)acetate(415912-62-8)
• EPA Substance Registry System: Methyl 2-(2-Methyl-4-nitrophenyl)acetate(415912-62-8)

Safety Data

• Hazardous Substances Data: 415912-62-8(Hazardous Substances Data)

Upstream product

• 77344-68-4 2-methyl-4-nitroacetophenone 

Downstream Products

• 156480-30-7 methyl 2-(2-methyl-4-nitrophenyl)acetate 
• 192650-52-5 (4-amino-2-methyl-phenyl)-acetic acid methyl ester 

Relevant articles and documents

2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

Use of EP4 receptor ligands in the treatment of IL-6 involved diseases

Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS

The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.